特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
914887

市場スポットライト:結核 (TB)

Market Spotlight: Tuberculosis (TB)

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 43 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.58円
市場スポットライト:結核 (TB)
出版日: 2020年08月21日
発行: Datamonitor Healthcare
ページ情報: 英文 43 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の結核 (TB) 治療薬市場について調査分析し、主な上市薬・パイプライン薬、治験、最近のイベント・アナリストの見解、将来・規制イベント、成功の確率、特許情報、10ヶ年予測、ライセンス・買収取引について、体系的な情報を提供しています。

概要

要点

疾患の背景

  • 疾患の定義
  • 患者のサブタイプ
  • 症状
  • リスク因子
  • 診断

治療

  • 抗結核薬
  • 手術

疫学

上市薬

パイプライン薬

最近のイベントとアナリストの見解

今後のイベント

主な規制イベント

成功の確率

ライセンス・資産取得取引

親特許

治験情勢

  • スポンサー:状況別
  • スポンサー:フェーズ別

参考文献

付録

目次
Product Code: DMKC0204837

This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2018, there were 13.9 million incident cases of tuberculosis (TB) worldwide, and forecasts that number to increase to 15.3 million incident cases by 2027.

Approved drugs in the TB space focus on a variety of targets. The majority of these drugs are administered via the oral route, with the remainder being topical and intravenous formulations.

The majority of industry-sponsored drugs in active clinical development for TB are in Phase II. Therapies in mid-to-late-stage development for TB focus on a wide variety of targets. The majority of pipeline drugs are administered via the oral route, with the remainder being tested in intramuscular and intradermal formulations.

The only high-impact upcoming event for drugs in the TB space is topline Phase II trial results for GSK3036656. The overall likelihood of approval of a Phase I antibacterial, mycobacterial, or fungal asset is 24.6%, and the average probability a drug advances from Phase III is 62.9%. Drugs, on average, take 9.6 years from Phase I to approval, compared to 9.1 years in the overall infectious disease space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for TB have been in the early and midphases of development, with 74% of trials in Phase I-II, and only 26% in Phase III-IV.

South Africa has a substantial lead in the number of TB clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.

Clinical trial activity in the TB space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for TB, with 17 trials.

GlaxoSmithKline leads industry sponsors with the highest overall number of clinical trials for TB.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient subtypes
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Anti-TB drugs
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Pretomanid for TB (June 6, 2019)
  • Pretomanid for TB (June 4, 2019)
  • Pretomanid for TB (April 18, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Pediatric Approvals In TB, Bladder Dysfunction, And Atopic Dermatitis
  • Mylan Gets Expert Panel Go-Ahead For Pretomanid In India
  • Global Approvals Snapshot: November 2019
  • Pretomanid Approval For Resistant TB: With Regulatory Flexibility Comes Usage Restrictions

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Pfizer Deal Covers Sutezolid For TB
  • Deals Shaping The Medical Industry, December 2019
  • Shionogi, Hsiri Expand Mycobacterial R&D Pact
  • BioNTech Gets Gates Foundation Funding For HIV, TB Drug Discovery

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Global trends in incident cases of tuberculosis, 2018-27
  • Figure 2: Overview of pipeline drugs for tuberculosis in the US
  • Figure 3: Pipeline drugs for tuberculosis, by company
  • Figure 4: Pipeline drugs for tuberculosis, by drug type
  • Figure 5: Pipeline drugs for tuberculosis, by classification
  • Figure 6: Key upcoming events in tuberculosis
  • Figure 7: Probability of success in the tuberculosis pipeline
  • Figure 8: Clinical trials in tuberculosis
  • Figure 9: Top 10 drugs for clinical trials in tuberculosis
  • Figure 10: Top 10 companies for clinical trials in tuberculosis
  • Figure 11: Trial locations in tuberculosis
  • Figure 12: Tuberculosis trials status
  • Figure 13: Tuberculosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of tuberculosis, 2018-27
  • Table 2: Global incident cases of tuberculosis with HIV, 2018
  • Table 3: Global incident cases of MDR/RR tuberculosis, 2018
  • Table 4: Marketed drugs for tuberculosis
  • Table 5: Pipeline drugs for tuberculosis in the US
  • Table 6: Pretomanid for TB (June 6, 2019)
  • Table 7: Pretomanid for TB (June 4, 2019)
  • Table 8: Pretomanid for TB (April 18, 2019)
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.